Efficacy and Safety of Aclidinium Bromide 400 µg Compared to Placebo and to Tiotropium Bromide in Patients With Stable Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Exclusion Criteria

• •Patients with no history or current diagnosis of asthma.
• •No evidence of an exacerbation within 6 weeks prior to the screening visit.
• •No evidence of clinically significant respiratory and/or cardiovascular conditions or laboratory abnormalities.
• •No contraindication to use of anticholinergic drugs such as known symptomatic prostatic hypertrophy, bladder neck obstruction or narrow-angle glaucoma.